ADAMTS13 and acquired thrombotic thrombocytopenic purpura: Its clinical use in acquired thrombotic thrombocytopenic purpura (TTP) demonstrates the therapeutic potential of directly targeting the vWF-ADAMTS13 axis in thrombotic disorders [75].